To date, four lead candidates have been selected based on in vitro and animal preclinical studies, stability, and manufacturing feasibility. Additional animal efficacy and toxicology testing of these lead candidates is underway, and CytRx is anticipating several milestones associated with the LADR candidates in the upcoming months and quarters.
November 2, 2017
· 5 min read